DSM-Firmenich AG

DSM-Firmenich has partnered with Meala to commercialize texturizing protein for meat alternatives, aiming to drive innovation in the plant-based food sector.

DSM-Firmenich AG has completed the sale of its stake in Feed Enzymes Alliance, marking a significant step towards achieving its long-term goals and positioning the company for continued growth and success.

DSM-Firmenich AG has updated its share repurchase program, aiming to buy back CHF 500 million worth of shares to optimize its capital structure and return value to shareholders.

DSM-Firmenich AG has made significant progress, with shareholders approving all resolutions and the company making headway on its share repurchase program, leading to growing investor optimism and a moderate increase in share value.

DSM-Firmenich AG’s Annual General Meeting saw shareholders overwhelmingly approve resolutions, boosting investor confidence and positioning the company for long-term growth.

DSM-Firmenich AG’s Q1 2025 earnings update shows a mixed bag of numbers, but the company’s management is optimistic about its future prospects and growing global presence.

DSM-Firmenich AG has made significant strides in the nutrition, health, and beauty sectors through strategic partnerships and investments, positioning itself for continued success and growth.

Dsm-Firmenich’s financial profile shows a strong valuation with a price-to-earnings ratio of 102.11 and a price-to-book ratio of 1.09062.

DSM-Firmenich solidifies its industry leadership through strategic investments and partnerships, including a new plant-derived exosome investment and the launch of a precision-fermented dairy protein ingredient.

DSM-Firmenich reports strong financial performance and ambitious sustainability goals, with plans for a €1 billion share buyback and a €2.4 billion adjusted EBITDA target for 2025.